Estimating the optimal age for infant measles vaccination

Area of Science:

• Epidemiology
• Mathematical Modeling
• Public Health

Background:

• Measles persists globally due to immunity gaps from incomplete or ineffective measles-containing vaccines (MCVs).
• The age of MCV1 administration impacts both vaccine failure risk and pre-vaccination infection risk.
• Current MCV1 recommendations are largely uniform worldwide, potentially missing opportunities for optimized disease control.

Purpose of the Study:

• To develop a novel mathematical model to estimate the optimal age for the first measles-containing vaccine dose (MCV1).
• To analyze the trade-off between vaccine failure and pre-vaccination infection risk based on MCV1 timing.
• To assess how local measles epidemiology influences the optimal MCV1 recommendation.

Main Methods:

• Designed a mathematical transmission model incorporating realistic vaccination delays and age-specific MCV1 effectiveness.
• Applied the model to diverse synthetic populations representing varying socioeconomic contexts.
• Analyzed the impact of local measles epidemiology, including vaccination coverage and transmission rates.

Main Results:

• Predicted a wide range of optimal MCV1 ages (6-20 months), contrasting with current uniform global recommendations.
• Demonstrated significant heterogeneity in optimal MCV1 ages across different populations.
• Identified that lower vaccination coverage and higher measles transmission necessitate an earlier optimal MCV1 age.

Conclusions:

• The optimal age for MCV1 is not universal and depends heavily on local measles epidemiology.
• Public health authorities can improve measles control by tailoring MCV1 schedules to specific population contexts.
• Mathematical modeling provides a valuable tool for optimizing vaccine strategies and closing immunity gaps.